Loading...
XNAS
PSTV
Market cap39mUSD
Dec 05, Last price  
0.65USD
1D
-0.76%
1Q
32.28%
Jan 2017
-99.99%
IPO
-100.00%
Name

Plus Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:PSTV chart
P/E
—
P/S
6.75
EPS
—
Div Yield, %
—
Shrs. gr., 5y
142.27%
Rev. gr., 5y
-3.61%
Revenues
6m
+18.54%
5,634,0007,927,0006,049,0004,528,0008,893,00010,627,0009,996,00014,501,00012,196,0007,598,00011,659,00011,380,0006,411,0002,983,0006,998,000303,0000224,0004,913,0005,824,000
Net income
-13m
L-2.54%
-26,538,000-25,447,000-28,672,000-30,036,000-23,216,000-27,494,000-32,451,000-32,279,000-26,177,000-37,368,000-18,744,000-22,046,000-22,686,000-12,634,000-12,742,000-9,348,000-14,331,000-20,838,000-13,316,000-12,978,000
CFO
-11m
L-17.87%
-1,101,000-16,483,000-29,995,000-33,389,000-23,807,000-23,574,000-35,323,000-32,193,000-34,563,000-30,330,000-20,468,000-19,533,000-18,128,000-11,975,000-5,906,000-8,434,000-10,280,000-12,972,000-12,851,000-10,554,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
URL
http://www.plustherapeutics.com/
IPO date
Aug 09, 2000
Employees
17
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT